Last updated on November 2016

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer


Brief description of study

This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countires.

Detailed Study Description

Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. NC-6004, a novel micellar cisplatin formulation, retains the activity but avoids the renal toxicity and neurotoxicity caused by the high peak Cmax concentrations of cisplatin. This trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer. The main hypothesis of this study is that NC-6004 plus gemcitabine combination is superior to gemcitabine alone in terms of overall survival in locally advanced or metastatic pancreatic cancer patients

Clinical Study Identifier: NCT02043288

Contact Investigators or Research Sites near you

Start Over

I-Chan Lee, COM

Taipei Medical University-Shuang-Ho Hospital, Ministry of Health and Welfare
Taipei, Taiwan
0.74miles
  Connect »

I-Chan Lee, COM

National Taiwan University Hospital
Taipei, Taiwan
4.15miles
  Connect »

I-Chan Lee, COM

Mackay Memorial Hospital
Taipei, Taiwan
5.43miles
  Connect »

I-Chan Lee, COM

Chang Gung Memorial Hospital, Linkou Branch
Taipei, Taiwan
5.62miles
  Connect »

I-Chan Lee, COM

Taipei Medical University Hospital
Taipei, Taiwan
6.16miles
  Connect »

I-Chan Lee, COM

Tri-Service General Hospital
Taipei, Taiwan
9.57miles
  Connect »